Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
about
INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.Cholestatic liver diseases: new targets, new therapiesDifferential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
P2860
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Superior reductions in hepatic ...... and obeticholic acid in mice.
@en
Superior reductions in hepatic ...... and obeticholic acid in mice.
@nl
type
label
Superior reductions in hepatic ...... and obeticholic acid in mice.
@en
Superior reductions in hepatic ...... and obeticholic acid in mice.
@nl
prefLabel
Superior reductions in hepatic ...... and obeticholic acid in mice.
@en
Superior reductions in hepatic ...... and obeticholic acid in mice.
@nl
P2093
P2860
P1433
P1476
Superior reductions in hepatic ...... and obeticholic acid in mice.
@en
P2093
Anthony Celeste
Hani Jouihan
Michelle L Boland
Peter Ravn
Sarah Will
Silvia Guionaud
Stephanie Oldham
P2860
P304
P356
10.1016/J.MOLMET.2017.09.001
P577
2017-09-14T00:00:00Z